MolMed S.p.A. and TTY Biopharm Company Ltd. (TTY) recently announced they signed an exclusive license and distribution agreement to import, use, market, sell and/or distribute Zalmoxis in Taiwan, Hong Kong, Vietnam, Philippines, Thailand, Malaysia, and Singapore. Zalmoxis has been approved by the European Commission (EMA) for the treatment of adult patients affected by leukaemia or for other high-risk haematological malignancies, in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT);this's also the first patient-specific cell therapy.